{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:52:27Z","timestamp":1793105547595,"version":"4.5.0"},"reference-count":43,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,7,7]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Corticosteroids, the most commonly prescribed treatment for sarcoidosis, are associated with significant toxicity, especially with long-term usage. New intervention trials designed to reduce or eliminate corticosteroids require pertinent and precise clinical trial end-points. However, consensus is lacking. The aim of the current study is to develop consensus for trial end-points in pulmonary sarcoidosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Delphi survey was developed by an Expert Panel of 30 sarcoidosis investigators. For Round 1, the panel created 97 statements regarding potential end-points for a clinical trial of symptomatic pulmonary corticosteroid-treated sarcoidosis patients. After anonymous voting in Round 2, the 97 statements were refined by all Stakeholders, including the Expert Panel and an additional 70 individuals interested in sarcoidosis therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After Round 2, the Expert Panel achieved consensus for combination end-points on 38 statements across six domains that supported the following end-points: prednisone reduction by 50% or discontinuation, 10% predicted or greater improvement in forced vital capacity % predicted, forced expiratory volume in 1\u2005s % predicted and diffusing capacity of the lung for carbon monoxide % predicted, and improvement in the King's Sarcoidosis Questionnaire Lung and General Health domains. Additionally, the majority of Stakeholders agreed to all statements which reached consensus by the Expert Panel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Utilising the Delphi technique, international sarcoidosis experts successfully achieved consensus for 38 specific clinical trial end-points which can be utilised in the development of novel steroid-sparing and eliminating therapies for pulmonary sarcoidosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.00943-2025","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:50:14Z","timestamp":1754581814000},"page":"2500943","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Pulmonary sarcoidosis clinical trial end-points: a Delphi study"],"prefix":"10.1183","volume":"66","author":[{"given":"Robert P.","family":"Baughman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3670-8097","authenticated-orcid":false,"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valeyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Sharp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Sellares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-1345","authenticated-orcid":false,"given":"Ogugua N.","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilario","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-9767","authenticated-orcid":false,"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid H.E.","family":"Korenromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"2025110508300645000_66.4.2500943.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04079-2020"},{"key":"2025110508300645000_66.4.2500943.2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.chest.2024.10.040","article-title":"Sarcoidosis treatment patterns in the United States: 2016\u20132022","volume":"167","author":"Sangani","year":"2025","journal-title":"Chest"},{"key":"2025110508300645000_66.4.2500943.3","doi-asserted-by":"crossref","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med"},{"key":"2025110508300645000_66.4.2500943.4","doi-asserted-by":"publisher","DOI":"10.1186\/s12961-018-0320-2"},{"key":"2025110508300645000_66.4.2500943.5","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-214348"},{"key":"2025110508300645000_66.4.2500943.6","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) . Multiple end-points in clinical trials: guidance for industry. 2022. www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-end-points-clinical-trials Date last accessed: 19 July 2025."},{"key":"2025110508300645000_66.4.2500943.7","first-page":"90","article-title":"Endpoints for clinical trials of sarcoidosis","volume":"29","author":"Baughman","year":"2012","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.8","first-page":"e2021034","article-title":"SCOUT \u2013 Sarcoidosis Outcomes Taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis","volume":"38","author":"Harman","year":"2021","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.9","first-page":"e2022030","article-title":"Identifying a core outcome set for pulmonary sarcoidosis research \u2013 the Foundation for Sarcoidosis Research \u2013 Sarcoidosis Clinical OUtcomes Taskforce (SCOUT)","volume":"39","author":"Harman","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019"},{"key":"2025110508300645000_66.4.2500943.11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2213-2600(23)00267-9","article-title":"High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study","volume":"12","author":"Desai","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025110508300645000_66.4.2500943.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025110508300645000_66.4.2500943.13","first-page":"e2021051","article-title":"World Association for Sarcoidosis and Other Granulomatous Disease (WASOG) Centers of Excellence","volume":"38","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.14","doi-asserted-by":"publisher","DOI":"10.1177\/0269216317690685"},{"key":"2025110508300645000_66.4.2500943.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"2025110508300645000_66.4.2500943.16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.2.333"},{"key":"2025110508300645000_66.4.2500943.17","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201962"},{"key":"2025110508300645000_66.4.2500943.18","first-page":"86","article-title":"A composite score to assess treatment response in pulmonary sarcoidosis: the Sarcoidosis Treatment Score (STS)","volume":"36","author":"Baughman","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s41030-023-00222-2","article-title":"Results from a phase 4, multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for the treatment of pulmonary sarcoidosis","volume":"9","author":"Mirsaeidi","year":"2023","journal-title":"Pulm Ther"},{"key":"2025110508300645000_66.4.2500943.20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.chest.2021.07.2162","article-title":"Riociguat for sarcoidosis-associated pulmonary hypertension: results of a 1-year double-blind, placebo-controlled trial","volume":"161","author":"Baughman","year":"2022","journal-title":"Chest"},{"key":"2025110508300645000_66.4.2500943.21","first-page":"e2022011","article-title":"Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/rheumatology\/kead373","article-title":"A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis","volume":"63","author":"Baker","year":"2024","journal-title":"Rheumatology"},{"key":"2025110508300645000_66.4.2500943.23","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00408-020-00394-7","article-title":"The St. George's Respiratory Questionnaire in pulmonary sarcoidosis","volume":"198","author":"Lo","year":"2020","journal-title":"Lung"},{"key":"2025110508300645000_66.4.2500943.24","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202006-607OC"},{"key":"2025110508300645000_66.4.2500943.25","doi-asserted-by":"crossref","first-page":"17534666221099737","DOI":"10.1177\/17534666221099737","article-title":"Leicester Cough Questionnaire validation and clinically important thresholds for change in refractory or unexplained chronic cough","volume":"16","author":"Nguyen","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"2025110508300645000_66.4.2500943.26","first-page":"e2023057","article-title":"D. Geraint James Lecture: the sarcoidosis saga: what insights from the past will guide us in the future","volume":"40","author":"Baughman","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025110508300645000_66.4.2500943.27","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060612"},{"key":"2025110508300645000_66.4.2500943.28","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.3.238"},{"key":"2025110508300645000_66.4.2500943.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"2025110508300645000_66.4.2500943.30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.1.24"},{"key":"2025110508300645000_66.4.2500943.31","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1164\/rccm.202109-2091OC","article-title":"Three-month FVC change: a trial endpoint for idiopathic pulmonary fibrosis based on individual participant data meta-analysis","volume":"205","author":"Khan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025110508300645000_66.4.2500943.32","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features","volume":"158","author":"Kouranos","year":"2020","journal-title":"Chest"},{"key":"2025110508300645000_66.4.2500943.33","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-221309"},{"key":"2025110508300645000_66.4.2500943.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.09.003"},{"key":"2025110508300645000_66.4.2500943.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00198-2023"},{"key":"2025110508300645000_66.4.2500943.36","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"2025110508300645000_66.4.2500943.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.10.037"},{"key":"2025110508300645000_66.4.2500943.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.05.004"},{"key":"2025110508300645000_66.4.2500943.39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00371-2019"},{"key":"2025110508300645000_66.4.2500943.40","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.rmed.2018.02.009","article-title":"Efficacy and safety of infliximab biosimilar Inflectra in severe sarcoidosis","volume":"138","author":"Schimmelpennink","year":"2018","journal-title":"Respir Med"},{"key":"2025110508300645000_66.4.2500943.41","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.10.4923"},{"key":"2025110508300645000_66.4.2500943.42","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181b97635"},{"key":"2025110508300645000_66.4.2500943.43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00943-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:30:21Z","timestamp":1762360221000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00943-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1183\/13993003.00943-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00943-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]}}}